Authors:
Giugliano, RP
McCabe, CH
Sequeira, RF
Frey, MJ
Henry, TD
Piana, RN
Tamby, JF
Jensen, BK
Nicolas, SB
Jennings, LK
Wise, RJ
Braunwald, E
Citation: Rp. Giugliano et al., First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: Results of theTIMI 15A and 15B trials, AM HEART J, 140(1), 2000, pp. 81
Authors:
Gibson, CM
Murphy, S
Menown, IBA
Sequeira, RF
Greene, R
Van de Werf, F
Schweiger, MJ
Ghali, M
Frey, MJ
Ryan, KA
Marble, SJ
Giugliano, RP
Antman, EM
Cannon, CP
Braunwald, E
Citation: Cm. Gibson et al., Determinants of coronary blood flow after thrombolytic administration, J AM COL C, 34(5), 1999, pp. 1403-1412
Authors:
Gibson, CM
Cannon, CP
Murphy, SA
Adgey, AAJ
Schweiger, MJ
Sequeira, RF
Grollier, G
Fox, NL
Berioli, S
Weaver, WD
Van de Werf, F
Braunwald, E
Citation: Cm. Gibson et al., Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10Btrial, AM J CARD, 84(9), 1999, pp. 976-980
Authors:
Cannon, CP
Gibson, CM
McCabe, CH
Adgey, AAJ
Schweiger, MJ
Sequeira, RF
Grollier, G
Giugliano, RP
Frey, M
Mueller, HS
Steingart, RM
Weaver, WD
Van de Werf, F
Braunwald, E
Citation: Cp. Cannon et al., TNK tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction - Results of the TIMI 10B trial, CIRCULATION, 98(25), 1998, pp. 2805-2814